Deregulated EGFR Signaling during Lung Cancer Progression: Mutations, Amplicons, and Autocrine Loops
- 25 July 2008
- journal article
- editorial
- Published by American Association for Cancer Research (AACR) in Cancer Prevention Research
- Vol. 1 (3), 156-160
- https://doi.org/10.1158/1940-6207.capr-08-0080
Abstract
No abstract availableThis publication has 37 references indexed in Scilit:
- Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung AdenocarcinomasCancer Prevention Research, 2008
- Intratumoral Epiregulin Is a Marker of Advanced Disease in Non–Small Cell Lung Cancer Patients and Confers Invasive Properties onEGFR-Mutant CellsCancer Prevention Research, 2008
- DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancersOncogene, 2008
- Sequential Molecular Changes during Multistage Pathogenesis of Small Peripheral Adenocarcinomas of the LungJournal of Thoracic Oncology, 2008
- Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomasJCI Insight, 2007
- Epidermal growth factor receptor mutations in lung cancerNature Reviews Cancer, 2007
- EGF–ERBB signalling: towards the systems levelNature Reviews Molecular Cell Biology, 2006
- Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancersInternational Journal of Cancer, 2006
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- ERBB receptors and cancer: the complexity of targeted inhibitorsNature Reviews Cancer, 2005